Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

Abstract Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye clinic in Switzerland between January 1st...

Full description

Bibliographic Details
Main Authors: Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Ophthalmology
Subjects:
Claims data
Health insurance
Cost analysis
Macular degeneration
Aflibercept
Ranibizumab
Online Access:http://link.springer.com/article/10.1186/s12886-018-0731-4

Internet

http://link.springer.com/article/10.1186/s12886-018-0731-4

Similar Items